Approval Expanded for Breast Cancer Drug Tykerb

To include certain postmenopausal women who need hormone therapy

Related Encyclopedia • Acidophilus • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis More... Related Healthscout Videos Growing Lungs in the Lab: Medicine's Next Big Thing? From Belly to Breast: Rebuilding After Cancer Laser Surgery Saves Twins Shaving off Cancer More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical • Damage of 'False-Positive' Mammograms Overlooked: Study • Smoking Scenes in Movies Light Up Smokers' Brains • Stents Show Promise in Treating Brain Blockages More...

MONDAY, Feb. 1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy.

The new approval is for Tykerb's use in combination with a second anti-cancer drug, Femara (letrozole), the agency said in a news release.

Text Continues Below

---

In women with HER2-positive breast cancer, those who received Tykerb and Femara more than doubled the time they lived without progression of their cancer, compared with those who received Femara alone (35 weeks versus 13 weeks), the FDA said.

Tykerb, first approved in 2007, is designed to block signals that tumor cells need to grow.

The drug is produced by GlaxoSmithKline.

More information

The FDA has more about this approval.

-- Scott Roberts